Tim Mills

Tim has more than 25 years of experience in venture capital, corporate management, and biomedical research. He joined Sanderling in 1998 and has had active roles within multiple portfolio companies including Stentor, acquired by Royal Philips Electronics (PHG), CardioNet (BEAT), Taligen Therapeutics, acquired by Alexion (ALXN), Neomend, acquired by C.R. Bard (BCR), Pulsar Vascular, acquired by Johnson & Johnson (JNJ) and Torax Medical, acquired by (JNJ). Prior to Sanderling, Tim served as Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics. Prior to Target, he served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare, now Edwards Life Science (EW). Tim was previously the Director of the Artificial Heart Program at University of California, Irvine Medical Center and faculty member at UC San Francisco. He received his Ph.D. in bioengineering from UC Berkeley and UCSF School of Medicine. Tim also received a M.S. in electrical engineering and computer science from UC Berkeley, and a B.S. in Electrical Engineering from University of Colorado Boulder.